UCBJY:OTO-UCB S.A. ADR (USD)

COMMON STOCK | Biotechnology | OTC Pink

Last Closing

USD 66.475

Change

0.00 (0.00)%

Market Cap

USD 13.74B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

UCB SA is a biopharmaceutical company engaged in discovery & development of medicines in the fields of oncology, central nervous system disorders. The products include Cimzia, Vimpat, Neupro, Keppra, and among others.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 568.62B
CSLLY CSL Ltd

N/A

USD 89.31B
CMXHF CSL Limited

N/A

USD 89.27B
UCBJF UCB SA

N/A

USD 25.40B
ARGNF argenx SE

N/A

USD 22.28B
GNMSF Genmab A/S

N/A

USD 18.12B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.48B
WXIBF WuXi Biologics

N/A

USD 7.17B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B

ETFs Containing UCBJY

DRDR:LSE iShares Healthcare Innova.. 2.02 % 0.00 %

N/A

USD 1.07B
IMV:LSE iShares Edge MSCI Europe .. 1.93 % 0.00 %

N/A

USD 0.72B
MVED:LSE iShares Edge MSCI Europe .. 1.93 % 0.00 %

N/A

USD 0.79B
MVEU:LSE iShares Edge MSCI Europe .. 1.93 % 0.00 %

N/A

USD 0.72B
IMVU:LSE iShares Edge MSCI Europe .. 1.93 % 0.00 %

N/A

USD 0.75B
HEAL:LSE iShares Healthcare Innova.. 1.78 % 0.00 %

N/A

USD 1.07B
AGED:LSE iShares Ageing Population.. 0.68 % 0.00 %

N/A

USD 0.47B
AGES:LSE iShares IV Public Limited.. 0.67 % 0.00 %

N/A

USD 0.47B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 52.47% 85% B 90% A-
Dividend Return 1.66% 75% C 47% F
Total Return 54.13% 86% B+ 90% A-
Trailing 12 Months  
Capital Gain 40.30% 84% B 86% B+
Dividend Return 3.70% 100% F 49% F
Total Return 44.00% 85% B 86% B+
Trailing 5 Years  
Capital Gain 73.11% 88% B+ 85% B
Dividend Return 10.13% 73% C 34% F
Total Return 83.25% 89% A- 85% B
Average Annual (5 Year Horizon)  
Capital Gain 6.45% 69% C- 63% D
Dividend Return 8.16% 71% C- 60% D-
Total Return 1.71% 29% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 25.96% 83% B 44% F
Risk Adjusted Return 31.43% 83% B 54% F
Market Capitalization 13.74B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector